IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. ID: 634398
DownloadNote - The PPT/PDF document "Personalized Therapy in Relapsed or Ref..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Next Slides
Relapsed and refractory myeloma
Improving therapy outcomes in relapsed/refractory
Relapsed or relapsed/refractory
Relapsed/refractory follicular lymphoma conundrums
The biology of relapsed and refractory multiple myeloma
Selecting therapy for relapsed/
Novel approaches for
Personalized cancer therapy
Ibrutinib : first-in class inhibitor of btk